ACAD Q3 2017 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q3 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+575.4% YoY

Gross Profit

$32M91.0% margin

Operating Income

-$66M-186.4% margin

Net Income

-$65M-183.4% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

+16.7%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$58M

Stock-Based Comp.

$20M

Balance Sheet

Total Assets

$414M

Total Liabilities

$36M

Stockholders' Equity

$377M

Cash & Equivalents

$113M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$5M	+575.4%
Gross Profit	$32M	$4M	+719.8%
Operating Income	-$66M	-$72M	+8.4%
Net Income	-$65M	-$72M	+8.9%